This change + N.Smedley initial director interest (and related parties) takes him to nearly 7m shares.
Great to have this kind of shareholder alignment backed up by actions.....ie cost cutting, optimising strategy, personnel and the most efficient path to selling products to asthma patients.
The new team is clearly gaining traction with investor discussions also. Some decent on market buying of recent times!
RSH Price at posting:
8.5¢ Sentiment: Buy Disclosure: Held
